TABLE 1.
Equivalence of Disease-Free and Recurrence Groups at Initial Cancer Diagnosis
| Variables | Disease-free (DF)
n = 90 Mean (%) |
Recurrence (R)
n = 30 Mean (%) |
|---|---|---|
| Sociodemographic | ||
| Mean age in yrs | 51.0 (9.7) | 52.0 (11.6) |
| Race (Caucasian) | (90.0) | (96.7) |
| Education in no. of yrs | 15.1 (2.6) | 14.8 (2.4) |
| Family Income (thousands of dollars/yr)) | 76.3 (87.9) | 59.7 (48.9) |
| Marital Status (Married) | (72.2) | (76.7) |
| Significant Other (Yes) | (83.3) | (83.3) |
| Prognostic | ||
| Months since initial diagnosis | 38.0 (17.3) | 36.6 (16.9) |
| Stage II vs. III (II) | (85.6) | (83.3) |
| Positive nodes | 3.1 (4.5) | 4.3 (8.5) |
| Tumor size in cm | 3.0 (1.7) | 3.6 (1.4) |
| ER/PR positive | (70.0) | (56.7) |
| Premenopausal status | (53.3) | (46.7) |
| Treatment received | ||
| Psychological intervention | (60.0) | (60.0) |
| Surgery, segmental mastectomy | (53.3) | (66.7) |
| Radiation therapy | (62.2) | (40.0) |
| Hormonal therapy | (76.7) | (70.0) |
| Chemotherapy | (84.4) | (86.7) |
| Doxorubicin | 75.6 | 73.3 |
| Cyclophosphamide | 83.4 | 86.7 |
| Methotrexate | 11.1 | 16.7 |
| 5-fluorouracil | 18.8 | 26.7 |
| Paclitaxel | 15.6 | 23.3 |
| Docetaxol | 3.3 | 3.3 |
| Chemotherapya: Average dose intensity received (mg/m2/wk) | ||
| Doxorubicin, n = 90 | 19.1 (4.2) | 18.8 (7.1) |
| Cyclophosphamide, n = 101 | 255.4 (204.6) | 210.9 (209.2) |
| Methotrexate, n 3 15 | 15.6 (3.3) | 11.3 (5.9) |
| 5-Fluorouracil, n = 25 | 201.3 (64.0) | 179.7 (69.9) |
| Paclitaxel, n = 22 | 63.6 (12.8) | 52.3 (22.5) |
| Docetaxol, n = 4 | 21.3 (5.3) | 16.3 (NA) |
ER/PR: estrogen/progesterone receptor status; NA: not applicable.
a
Mean based on number of patients who were recommended treatment.